Lyell Immunopharma, Inc.
LYEL
$12.86
$0.161.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 53.73% | 26.68% | 12.87% | 6.82% | 13.96% |
| Total Depreciation and Amortization | -32.23% | -52.31% | -45.17% | -36.03% | -31.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -537.11% | -24.51% | 104.99% | 58.36% | -78.83% |
| Change in Net Operating Assets | 88.65% | 1,876.47% | -113.11% | 8.18% | -195.15% |
| Cash from Operations | 29.65% | 31.73% | 18.45% | 9.54% | -30.28% |
| Capital Expenditure | 63.82% | -590.91% | -5.08% | 49.24% | -720.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -31.42% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -74.94% | -88.09% | 59.23% | -71.73% | 216.53% |
| Cash from Investing | -74.98% | -158.62% | 74.61% | -71.90% | 215.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -48.97% | -- | -78.65% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,172,100.00% | -49.20% | -- | -78.77% | -96.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.69% | -1,046.18% | 174.79% | -378.17% | 173.66% |